




RealRate

PHARMACEUTICAL 2021

NovaBay Pharmaceuticals Inc.
Rank 314 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 356% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 411% points.

The company's Economic Capital Ratio, given in the ranking table, is -344%, being 10% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	14,242
Cost of Goods Sold	3,970
Intangible Assets	0
Liabilities, Current	2,833
Liabilities, Non-Current	87
Other Assets	912
Other Compr. Net Income	0
Other Expenses	11,394
Other Liabilities	0
Other Net Income	608
Property and Equipment	84
Research and Development	285
Revenues	9,934
Selling, General and Administrative Expense	5,932

Output Variable	Value in 1000 USD
Assets	15,238
Liabilities	2,920
Expenses	21,581
Stockholders Equity	12,318
Net Income	-11,039
Comprehensive Net Income	-11,039
Economic Capital Ratio	-344%